| Similar Articles |
|---|
 |
Chemistry World
November 19, 2012 |
Reckitt steps into Schiff deal Bayer's $1.2 billion bid for Schiff Nutrition, a US company specialising in vitamins and nutritional supplements, could be in trouble following a higher bid from another company.   |
Chemistry World
November 23, 2012
Andrew Turley |
Schiff seals deal with Reckitt The billion-dollar tussle between German healthcare giant Bayer and UK consumer products firm Reckitt Benckiser over Schiff Nutrition has been resolved with Reckitt winning out. |
Commercial Investment Real Estate
Mar/Apr 2012
Oscar J. Franck Terrazas |
Mexico or Brazil? Investors may be surprised at the comparison of these two countries. |
Chemistry World
July 28, 2014
Phillip Broadwith |
Reckitt Benckiser to spin out US pharma arm Consumer health firm Reckitt -- Benckiser plans to spin off its US pharmaceutical division, whose primary product is heroin-substitute Suboxone. |
Chemistry World
October 31, 2012
Andrew Turley |
Bayer spends $1.2bn on supplement maker German healthcare giant Bayer has struck a deal to buy Schiff Nutrition, a US company specializing in vitamins and nutritional supplements, for $1.2 billion. |
BusinessWeek
September 27, 2004 |
A Mexico-Japan Trade Deal After six years in the making, Mexico and Japan are finally set to sign a Free Trade Agreement covering most industrial products along with certain agricultural goods -- only the second such deal for Japan. |
The Motley Fool
January 6, 2005
Rich Duprey |
Bristol-Myers Relieves Its Headache The pharmaceutical giant is selling its consumer medicines division. Though the division represents only about 2% of Bristol-Myers' $21 billion sales, the company overall has seen sales falter and its stock decline some 12% last year. |
The Motley Fool
December 11, 2007
Brian Orelli |
Mucous Migrates East U.K.-based Reckitt Benckiser purchases Adams Respiratory Therapeutics, makers of Mucinex, for $2.3 billion. |
Chemistry World
May 9, 2014
Andy Extance |
Bayer wins race to buy Merck & Co consumer care Germany's Bayer has won a bidding contest for US giant Merck & Co's consumer care business unit, seemingly thanks to a heart drug collaboration sweetener. |
Chemistry World
January 11, 2016
Phillip Broadwith |
GSK's ViiV to buy HIV drugs from BMS Bristol-Myers Squibb has agreed to sell its entire portfolio of investigational HIV drugs as the company seeks to exit research in virology. |
The Motley Fool
July 28, 2005
Stephen D. Simpson |
Bristol-Myers' Road to Better Health Bristol-Myers looks toward 2007 and a resumption of real growth. For now, things could be a lot worse. At least investors can't say they're not getting paid to be patient. |
BusinessWeek
July 21, 2003
Geri Smith |
Private Equity: Rekindling a Latin Love Affair Funds are again funneling money south, especially into Mexico |
BusinessWeek
July 5, 2004 |
Where To Dig Up Latin Gems How should investors play Latin America, given an impending rise in U.S. interest rates and a projected slowdown in commodities demand from Asia? |
Chemistry World
May 23, 2006
Katharine Sanderson |
Brazil and UK Team up Brazil is ready and mature to join the international science arena, the Brazilian science minister told leading UK and Brazilian scientists and politicians yesterday. |
CRM
December 20, 2004
Coreen Bailor |
The Next CRM Hot Spot? Latin American companies add flavor to their services, helping to nurture their customer relationships and maximize sales opportunities. |
Investment Advisor
January 2006
Palash R. Ghosh |
S&P Mutual Fund Sector Focus: Latin Funds Soar Northward Investing in Latin American stocks has been very lucrative the past few years. The continent offers immense commodities and natural resources, a cheap labor force, and an improving economic infrastructure: T. Rowe Price Latin America Fund... etc. |
IDB America
January 2004
Eduardo Lora |
The hidden danger in China's economy The concern is that Chinese factories are displacing the maquiladoras of Mexico and Central America as the preferred source of manufactured goods destined for the United States. Also, some blame China's growth for the sharp drop in foreign direct investment to Latin America. |
The Motley Fool
September 17, 2008
Brian Orelli |
IPO? In This Market? Bristol-Myers continues with plans to spin off its nutritionals business. |
Financial Planning
November 1, 2011
Donald Jay Korn |
The Latin Quarter Fortunately, unleveraged exposure to the region has been more than ample over the past decade. Planners with clients who can live with volatility might want to look south of the border. |
Bank Technology News
May 2001
Daniel Joelson |
Online Trading Craze in Latin America The market goes from hope to fear and back... |
The Motley Fool
November 28, 2007
Nathan Parmelee |
A Sea of Tranquility in a Financial Storm Some of the strongest economies in the world can now be found in Latin America, where companies have been largely immune to the volatility most companies around the world have experienced. |
Chemistry World
October 19, 2015
Philippa Matthews |
BMS agrees $1.7bn immuno-oncology collaboration Bristol-Myers Squibb has entered into a worldwide license and collaboration with Five Prime Therapeutics to develop and commercialize Five Prime's colony stimulating factor 1 receptor (CSF1R) antibodies. |
The Motley Fool
February 22, 2010
Brian Orelli |
A Huge Business Wrapped Up in Tiny Packages Drug investors shouldn't forget about over-the-counter products. |
The Motley Fool
July 13, 2011
Neha Chamaria |
Your Portfolio Better Get Ready to Habla Espanol o Portugues Keep an eye on how companies take advantage of growth in Latin America. |
The Motley Fool
October 4, 2007
Nathan Parmelee |
Forget China China is not the only hot country to invest in. Mexico, Brazil, and the Philippines all offer above-average growth potential. |
The Motley Fool
May 10, 2011
Shubh Datta |
Wal-Mart Pins Hopes on Brazil's Mighty Potential Wal-Mart is set to invest close to $756 million in the South American giant. |
BusinessWeek
March 22, 2004
Geri Smith |
Latin America: It's In Play Again, Too Latin America is again becoming a place to invest in. |
Chemistry World
December 20, 2013
Patrick Walter |
AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture. |
Chemistry World
April 4, 2013
Phillip Broadwith |
Amylin headquarters to close with further job losses Bristol-Myers Squibb has confirmed that it will be closing the site in San Diego, US, which was formerly the corporate headquarters of biotech firm Amylin. |
The Motley Fool
April 28, 2008
Brian Lawler |
Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results. |
Investment Advisor
March 2007
Kathleen M. McBride |
Native Speaker Gonzalo Pangaro, portfolio manager of the $2.3 billion T. Rowe Price Latin America Fund, is fluent in the languages and politics of Latin America and in portfolio construction. |
The Motley Fool
February 1, 2008
Brian Lawler |
Credit Crisis Bites Big Pharma Bristol-Myers Squibb takes a $275 million writedown in its investment portfolio for the quarter. |
The Motley Fool
January 29, 2010
Brian Orelli |
All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time. |
The Motley Fool
November 1, 2004
Brian Gorman |
Bristol-Myers Stays the Course The pharma remains downbeat on its outlook through 2006, but two promising compounds could lift the company's fortunes. |
